An immunogenic composition comprising a synthetic consensus antigen for a follicle stimulating hormone receptor (FSHR) protein rich in many ovarian cancer sub-types is provided herein. Methods of treating this by administering the immunogenic composition to a subject in need of treatment of a tumor associated pathology are also disclosed herein.
展开▼